全球停用二价口服脊灰疫苗:2000至2025年模型研究综述
该综述系统回顾了2000至2025年间116篇模型研究,聚焦全球停用二价口服脊灰疫苗(bOPV)的规划与风险管理。研究强调停用前需开展多年高质量补充免疫活动并加强常规免疫、引入至少两剂免疫原性有效的IPV,停用后需维持高IPV覆盖率、快速疫情响应和敏感监测。这些证据支持了免疫战略咨询专家组对全球脊灰消灭倡议bOPV停用政策框架的认可。
要点
- 停用bOPV前应连续多年开展高质量补充免疫活动,覆盖率和目标年龄组需各国定制。
- 停用前须加强常规免疫并引入至少两剂免疫原性有效的IPV方案。
- 停用后应维持高IPV覆盖率、快速同型OPV疫情响应及严格封存措施。
核心结论
- 模型研究支持在停用bOPV前实施多年高质量补充免疫活动并加强常规免疫和IPV接种。
- 停用后需维持高IPV覆盖率、快速高质量疫情响应和敏感监测及充足疫苗储备。
- 上述证据支持了免疫战略咨询专家组对全球脊灰消灭倡议bOPV停用政策框架的认可。
研究设计与样本
- comprehensive review of modeling studies published from 2000 to 2025.
- 共纳入116篇符合纳入标准的文献。
- 比较了模型类型与假设,并围绕停用前规划、停用后风险管理、监测和疫苗储备等主题综合模型见解。
主要发现
- 停用前需实施多年高质量bOPV补充免疫活动,覆盖水平和目标年龄组因国家而异。
- 停用前应加强常规免疫,提高覆盖率并引入至少两剂免疫原性有效的IPV方案。
- 停用后需维持高常规免疫IPV覆盖率、使用可用同型OPV快速高质量疫情响应并执行严格封存方案。
- 停用前、中、后均应确保敏感监测和充足疫苗储备。
关键数值与推荐
- 停用前实施多年高质量bOPV补充免疫活动,覆盖水平和目标年龄组需国家定制。
- 停用前加强常规免疫并引入至少两剂免疫原性有效的IPV方案。
- 停用后维持高IPV覆盖率、快速高质量同型OPV疫情响应和严格封存方案。
- 停用前、中、后确保敏感监测和充足疫苗储备。
临床怎么用
- 在bOPV停用规划中,应优先安排多年高质量补充免疫活动并同步加强常规免疫。
- 停用前应确保IPV至少两剂接种方案落地并维持高覆盖率。
- 停用后应保持敏感监测、快速疫情响应能力和充足疫苗储备。
局限性
- 如何测量人群免疫并定义考虑次国家异质性的停用准备阈值尚不明确。
- 全球同步停用是否必要或地理分阶段方法能否达到相当的风险降低尚不清楚。
- 新型OPV制剂的可用性如何影响停用策略尚不明确。
- 未来研究应纳入次国家数据、反映新疫苗特征并整合多种建模方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral polio vaccine (OPV) has been central to the Global Polio Eradication Initiative (GPEI)'s efforts due to its ability to interrupt transmission. Yet, because OPV contains live-attenuated virus, its continued use carries risks, especially the emergence of circulating vaccine-derived poliovirus (cVDPV) in under-vaccinated communities. To reduce these risks, phased OPV cessation by serotype began in 2016 with the global "switch" from trivalent OPV (containing types 1, 2, and 3) to bivalent OPV (bOPV, containing types 1 and 3) after the eradication of wild poliovirus type 2. However, continued post-switch cVDPV type 2 outbreaks demonstrated the complexities of safe OPV cessation. Along with persistent wild poliovirus type 1 transmission and cVDPV outbreaks of other serotypes, these experiences underscored the need for evidence-based strategies to guide bOPV cessation. AREAS COVERED: We conducted a comprehensive review of modeling studies published from 2000 to 2025 that inform OPV cessation planning. 116 articles met our inclusion criteria. These studies examined OPV cessation's prerequisites, follow-up actions, and response strategies. We compared model types and assumptions. We synthesized modeling insights across decision-relevant themes: pre-cessation planning of routine immunization (RI) and supplementary immunization activities (SIAs), post-cessation risk management, surveillance, and vaccine stockpiling. CONCLUSIONS: The included articles emphasized: (i) implement multiple, high-quality bOPV SIAs over several years until cessation, with coverage levels and target age groups tailored to countries; (ii) strengthen RI before cessation by increasing coverage and introducing a immunologically effective IPV schedule of at least two doses; (iii) maintain high RI IPV coverage, rapid and high-quality outbreak response using available homotypic OPV, and strict containment protocols after cessation; (iv) ensure sensitive surveillance and adequate vaccine stockpiles before, during, and after cessation. These findings informed the Strategic Advisory Group of Experts on Immunization in its endorsement of GPEI's bOPV cessation policy framework. Nonetheless, important gaps remain, including how to measure population immunity and define target thresholds for cessation readiness considering subnational heterogeneity, whether globally synchronized cessation is necessary or geographically phased approaches could achieve comparable risk reduction, and how the availability of novel OPV formulations may influence cessation strategies. Future studies should incorporate subnational data, reflect new vaccine characteristics, and integrate diverse modeling approaches to guide more context-specific decisions.
引用
- Sun Y, Keskinocak P, Peak CM, et al. Global cessation of bivalent oral polio vaccine (bOPV): A comprehensive review of modeling studies from 2000 to 2025. Vaccine. 2026. PMID: 42208276. doi:10.1016/j.vaccine.2026.128707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。